essential_thrombocytosis
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| essential_thrombocytosis [2025/06/19 07:32] – [treatment] gary1 | essential_thrombocytosis [2026/05/10 19:34] (current) – [introduction] wh | ||
|---|---|---|---|
| Line 15: | Line 15: | ||
| * the thrombopoietin gene (THPO) | * the thrombopoietin gene (THPO) | ||
| * the thrombopoietin receptor gene (MPL) - include MPL-P106L, MPL-S505N (this may increase thrombotic risk), and MPL-W515R, as well as the polymorphism MPL-K39N termed MPL Baltimore | * the thrombopoietin receptor gene (MPL) - include MPL-P106L, MPL-S505N (this may increase thrombotic risk), and MPL-W515R, as well as the polymorphism MPL-K39N termed MPL Baltimore | ||
| + | * possibly POT1 mutation (([[https:// | ||
| * JAK2 kinase (V617F) gene - not inherited itself as this is a somatic mutation, but some families have familial predisposition | * JAK2 kinase (V617F) gene - not inherited itself as this is a somatic mutation, but some families have familial predisposition | ||
| *prognosis is much better than for [[myelofibrosis]] with 10 yr survival rates > 90%, and 20 yr survival rates around 75% for JAK-2 or MPL mutations, and ~85% for CALR mutations | *prognosis is much better than for [[myelofibrosis]] with 10 yr survival rates > 90%, and 20 yr survival rates around 75% for JAK-2 or MPL mutations, and ~85% for CALR mutations | ||
essential_thrombocytosis.txt · Last modified: 2026/05/10 19:34 by wh